Literature DB >> 6430018

Effects of intravenous progesterone infusions on the epileptic discharge frequency in women with partial epilepsy.

T Bäckström, B Zetterlund, S Blom, M Romano.   

Abstract

Earlier work showed that in a group of women suffering from partial epilepsy, there is a decrease in seizure frequency during the luteal phase of the menstrual cycle. Moreover, iv progesterone infusions decrease the discharge frequency from penicillin epileptic foci in cats, when given in doses that reach plasma concentrations as observed during pregnancy. In the present study, iv progesterone infusions, reaching plasma concentrations as during the luteal phase, were given to 7 women with partial epilepsy. The inclusion criterion was that they should have more than one epileptic discharge per 5 min on an ordinary EEG . A 6 h EEG-registration was made. Blank and progesterone solutions were infused for 2 h respectively and the progesterone infusion was followed by a 2 h EEG recording period. 4 of the 7 patients showed a significant decrease in spike frequency during the infusion. In the patients not showing this effect, the plasma progesterone binding capacity was high. The 2 patients with the most marked progesterone effect had low progesterone binding capacity and no antiepileptic treatment. Somnolence during the test might also have influenced the results in 2 of the patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6430018     DOI: 10.1111/j.1600-0404.1984.tb07807.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  30 in total

1.  Effect of age on synthesis of the GABAergic steroids 5-alpha-pregnane-3,20-dione and 5-alpha-pregnane-3-alpha-ol-20-one in rat cortex in vitro.

Authors:  H J Stuerenburg; U Fries; F Iglauer; K Kunze
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

2.  Allopregnanolone concentration and mood--a bimodal association in postmenopausal women treated with oral progesterone.

Authors:  Lotta Andréen; Inger Sundström-Poromaa; Marie Bixo; Sigrid Nyberg; Torbjörn Bäckström
Journal:  Psychopharmacology (Berl)       Date:  2006-05-25       Impact factor: 4.530

3.  A novel therapeutic approach for treatment of catamenial epilepsy.

Authors:  Suchitra Joshi; Huayu Sun; Karthik Rajasekaran; John Williamson; Edward Perez-Reyes; Jaideep Kapur
Journal:  Neurobiol Dis       Date:  2017-12-21       Impact factor: 5.996

4.  Female reproductive factors and risk of seizure or epilepsy: data from the Nurses' Health Study II.

Authors:  Barbara A Dworetzky; Mary K Townsend; Page B Pennell; Jae H Kang
Journal:  Epilepsia       Date:  2011-11-02       Impact factor: 5.864

Review 5.  Sex differences in the anticonvulsant activity of neurosteroids.

Authors:  Doodipala Samba Reddy
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

6.  Neuroprotection against excitotoxic brain injury in mice after ovarian steroid depletion.

Authors:  P Elyse Schauwecker; Ruth I Wood; Ariana Lorenzana
Journal:  Brain Res       Date:  2009-02-21       Impact factor: 3.252

Review 7.  Influence of sex hormones on brain excitability and epilepsy.

Authors:  A Verrotti; G Latini; R Manco; M De Simone; F Chiarelli
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

Review 8.  Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations.

Authors:  James W McAuley; Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 9.  Neurosteroids and their role in sex-specific epilepsies.

Authors:  Doodipala Samba Reddy
Journal:  Neurobiol Dis       Date:  2014-06-21       Impact factor: 5.996

10.  Interaction of androsterone and progesterone with inhibitory ligand-gated ion channels: a patch clamp study.

Authors:  Elke Ziegler; M Bodusch; Y Song; K Jahn; H Wolfes; S Steinlechner; R Dengler; J Bufler; K Krampfl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-08-25       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.